Jonah Feldman

Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.

Elinzanetant, already approved for menopause-related VMS, is being considered to address hot flashes associated with adjuvant breast cancer endocrine therapy.

Durvalumab plus enfortumab vedotin improved EFS and OS in MIBC and will be considered for FDA approval in the fourth quarter of 2026.

In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.

FDA approves belzutifan plus lenvatinib for advanced clear cell RCC after PD-1/PD-L1 therapy, based on PFS and response rate benefit vs cabozantinib.

LRRC15-targeting ADC SOT106 gains FDA fast track and orphan status for sarcomas, showing preclinical promise as it heads into a first-in-human trial.

For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.

NCCN guidelines indicate rusfertide for patients who are intolerant to phlebotomy or who receive frequent phlebotomy, regardless of risk status.

Preview the 2026 International Myeloma Society meeting: the IMS/IMWG cure consensus, plenary session phase 3 trials, and new bispecific/CAR T myeloma findings.

The FDA's Expedited Investigational New Drug (IND) Pilot Program pairs trial sponsors and research institutions to promote phase 1 trials in the US.

The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.

Osimertinib was associated with a 47% reduction in risk of death among patients with stage II-IIIA EGFR-mutated non–small cell lung cancer at 8 years.

The FDA approved the topical gel with the brand name Ameluz for use with photodynamic therapy for basal cell carcinoma; it is already approved for actinic keratosis.

The B7-H3–directed antibody-drug conjugate risvutatug rezetecan improved overall survival in the China-based ARTEMIS-008 study of relapsed extensive-stage small cell lung cancer presented at WCLC.

The FDA has approved Omcazio, a capsule-based formulation of cabozantinib as a laurylsulfate salt, that demonstrated bioequivalence to the existing tablet.

The UK's OPTIMUM trial showed significant differences with a more aggressive treatment regimen for high-risk newly diagnosed multiple myeloma, based on long-term follow-up.

For Prostate Cancer Awareness Month, Manojkumar Bupathi, MD, MS, examines how oncologists are changing practice after 4 key FDA approvals and a trend toward biomarker-driven therapy.

In the SURF302 trial, favorable response rates were seen in the single- and multiple-marker-lesion population, justifying further investigation in the adjuvant bladder cancer setting.

In the pivotal phase 2 QUINTESSENTIAL trial, arlo-cel, a GPRC5D-targeted CAR T-cell therapy, showed favorable overall response rate in patients who had received multiple prior lines including BCMA-targeted therapy.

A City of Hope study found success in promoting skin cancer screening to transplant survivors, Saro Armenian, MD, explains.

OST-HER2, an investigational immunotherapy, yielded favorable overall survival outcomes ahead of an FDA meeting to consider its basis for approval.

Published results from the PARADIGM study of azacitidine/venetoclax showed an event-free survival benefit and lower hemorrhage rates in acute myeloid leukemia.

AUA/SUO's 2026 NMIBC guideline amendment adds 40 statements on risk stratification, surveillance intervals, urinary biomarkers, and emerging BCG-unresponsive therapies.

Etentamig surpassed standard therapy in terms of response rate and progression-free survival in the phase 3 CERVINO trial for relapsed/refractory multiple myeloma.

Daraxonrasib showed dose-dependent objective response rates of 31% to 37% in previously treated RAS-mutant NSCLC, per phase 1/2 trial data published in the New England Journal of Medicine.

Rezatapopt hit a 46% ORR in TP53 Y220C–mutated ovarian cancer in the PYNNACLE trial, with an FDA filing expected in Q1 2027.

The OS findings follow the recent FDA approval of zanidatamab with or without tislelizumab in HER2-positive gastroesophageal cancer.

A JAK inhibitor with a favorable safety profile demonstrated clinical activity in patients with chronic graft-vs-host disease.

FDA clears IND for ADI-212, an off-the-shelf PSMA-targeted gamma-delta CAR T for metastatic castration-resistant prostate cancer, as phase 1/2 trial readies 2026 enrollment.

The LRRC15-targeting antibody-drug conjugate will be investigated in a first-in-human trial later this year.